

Overexpression of the Inhibitor Protein IF₁ in AS-30D Hepatoma Produces a Higher Association with Mitochondrial F₁F₀ ATP Synthase Compared to Normal Rat Liver: Functional and Cross-Linking Studies

Concepción Bravo,¹ Fernando Minauro-Sanmiguel,¹ Edgar Morales-Ríos,¹ José S. Rodríguez-Zavala,¹ and José J. García^{1,2}

Received January 9, 2004; accepted January 15, 2004

According to functional studies, the higher IF₁ content reported in mitochondria of cancerous cells is supposed to induce a higher association with the F₁F₀ complex than in normal cells and therefore a better inhibition of its ATPase activity. The first structural evidence supporting this prediction is here presented. Densitometric analyses of Western blotting experiments indicated a 2-fold increase in IF₁ content of AS-30D submitochondrial particles compared to normal rat liver controls. The ratio of IF₁/F₁ α subunit increased similarly as judged by Western blot analyses. This IF₁ overexpression correlated with a slower rate of IF₁ release (F₁F₀-ATPase activation) from the F₁F₀ complex in AS-30D than in normal rat liver submitochondrial particles. The IF₁-IF₁, γ -IF₁, and α -IF₁ cross-linkages previously formed with dithiobis(succinimidylpropionate) in bovine F₁F₀I and IF₁ complexes (Minauro-Sanmiguel, F., Bravo, C., and García, J. J. (2002). *J. Bioenerg. Biomembr.* **34**, 433–443) were reproduced in the F₁F₀I-ATP synthase of hepatoma AS-30D cells. However, a much lower yield of IF₁ cross-linkages was found in normal rat liver particles which made them almost undetectable in SMP as well as in the immunoprecipitated F₁F₀I complex. Modeling *in vivo* IF₁ overexpression of cancerous cells by *in vitro* reconstitution of excess recombinant IF₁ with rat liver submitochondrial particles devoid of IF₁ reproduced the same IF₁ cross-linkages observed in AS-30D particles.

KEY WORDS: Inhibitor protein; IF₁; F₁F₀-ATP synthase; cancer; cross-linking; AS-30D.

INTRODUCTION

The mitochondrial F₁F₀ complex synthesizes most of the ATP required by the cell by using Mg²⁺ ADP and Pi as substrates. Because it is a reversible rotary motor enzyme, it can synthesize or hydrolyze ATP according to the working conditions. Thermodynamically, the enzyme is biased to ATP synthesis by the proton motive force ($\Delta\mu_{H^+}$) generated by the respiratory chain. The F₁F₀-ATP synthase is also driven by the constant supply

of ADP and Pi by adenine nucleotide (ANT) and Pi carriers, respectively. Furthermore, a recent report indicates the presence of an ATP synthasome supercomplex containing F₁F₀, ANT, and Pi carriers (Ko *et al.*, 2003) which ensures a more efficient ATP synthesis turnover. As a further mechanism to prevent ATP hydrolysis, the mitochondrial enzyme contains an inhibitor protein (IF₁) which arrests the forward and backward functioning of

Abbreviations used: CAPS, 3-(Cyclohexylamino)-1-propanesulfonic acid; DSP, dithiobis(succinimidylpropionate); DTT, dithiothreitol; EDTA, ethylenediamine-tetraacetic acid; F₁, the soluble F₁-ATPase; F₁I, the complex of soluble F₁-ATPase containing the inhibitor protein; F₁F₀I, the native ATP synthase containing the inhibitor protein; IF₁, the inhibitor protein of the mitochondrial ATP synthase; mAb, monoclonal antibody; SDS-PAGE, denaturing sodium dodecyl sulphate polyacrylamide gel electrophoresis; SMP, submitochondrial particles; WB, Western blot.

¹Departamento de Bioquímica, Instituto Nacional de Cardiología, "Ignacio Chávez," México, México.

²To whom correspondence should be addressed at Departamento de Bioquímica, Instituto Nacional de Cardiología, Juan Badiano # 1, Col. Sección XVI, México D.F. 14080, México; e-mail: jjgarcia.trejo@yahoo.com.

the enzyme when the $\Delta\mu_{H^+}$ drops (Gómez-Puyou *et al.*, 1979; Harris *et al.*, 1979; Pullman and Monroy, 1963; Schwerzmann and Pedersen, 1986). Re-establishment of $\Delta\mu_{H^+}$ releases the inhibitory action of IF₁ (Harris *et al.*, 1979; Gómez-Puyou *et al.*, 1979) and favors ATP synthesis. Therefore, *in vivo* IF₁ produces a net inhibition of ATP hydrolysis. Physiologically, IF₁ protects the heart, and presumably other tissues, from ischemia-reperfusion injury by preventing cellular ATP depletion (Ala-Rämi *et al.*, 2003; Rouslin, 1991). IF₁ inhibits more efficiently the F₁F₀-ATPase in submitochondrial particles isolated from ischemic hearts in comparison with nonischemic controls (Ala-Rämi *et al.*, 2003; Rouslin, 1991). As a further tissue specific regulation, the expression of IF₁ relative to ATP synthase is higher in the heart than in other organs (Rouslin and Broge, 1996). This is in accordance with the high energy demand and fast regulation required by the heart. In contrast, it has been shown that in a more glycolytic tissue like rat liver, the IF₁ is subexpressed relative to the ATP synthase (Schwerzmann *et al.*, 1982), and therefore the ATPase activity of the rat liver F₁F₀ is higher.

On the other hand, several reports have shown that IF₁ is overexpressed in mice (Capuano *et al.*, 1997; Chernyak *et al.*, 1991; Luciakova and Kuzela, 1984) and human (Chernyak *et al.*, 1994) cancerous cells. On the basis of F₁F₀-ATPase determinations, it has been proposed that the excess of IF₁ should prevent ATP hydrolysis more efficiently in cancerous cell lines than in normal cells (Chernyak *et al.*, 1991). Since many cancer cell lines exhibit a high glycolytic capacity, it has been concluded that IF₁ inhibits hydrolysis of the glycolytic ATP in these cells (Chernyak *et al.*, 1991). However, there is no structural evidence supporting a better productive interaction of IF₁ with the ATP synthase in cancerous cells. In this work we developed a new method to determine the productive association of the endogenous IF₁ with the ATP synthase in submitochondrial particles (SMP). The AS-30D cell line from hepatocellular carcinoma origin (Chang *et al.*, 1967; Smith *et al.*, 1970) was used in parallel to normal rat liver to isolate mitochondria and SMP. We took advantage of previous cross-linking studies of IF₁ with rotor (γ and ϵ) and stator (α) subunits of the ATP synthase that we described before with bovine heart SMP (Minauro-Sanmiguel *et al.*, 2002). We found that the higher expression of IF₁ in rat AS-30D hepatoma compared to rat liver produces a better productive association of IF₁ with the F₁F₀ complex. This was demonstrated by greater IF₁-rotor/stator cross-linking yields as well as by ATPase activity assays.

MATERIALS AND METHODS

Rat liver mitochondria and digitonin-extracted mitochondria from AS-30D hepatoma were obtained as

described before (Moreno-Sánchez, 1985; Moreadith and Fiskum, 1984). "Mg-ATP" submitochondrial particles (SMP) containing the endogenous IF₁ were prepared as described elsewhere (García *et al.*, 1995). The endogenous IF₁ was released from the F₁F₀-ATPase of SMP by incubation in "Activation Media" containing Sucrose 125 mM, Tris-SO₄ 60 mM, EDTA 2 mM, KCl 100 mM, and ATP 10 mM, pH 8.0. SMP were incubated at 40°C and aliquots were withdrawn at indicated times for spectrophotometric measurement of ATPase activity (García *et al.*, 1995). Activity measurements of liver and hepatoma SMP were carried out immediately after SMP preparation avoiding cycles of freezing and thawing. This procedure improved the stability of IF₁ inhibition and the maximal ATPase activity obtained after activation. SMP devoid of IF₁ were obtained by sonication and incubation in Activation Media as described elsewhere (Klein *et al.*, 1982).

Cross-Linking of IF₁ With Subunits of the F₁F₀I Complex in SMP

Cross-linking experiments were carried out with DSP (Pierce) in Sucrose-phosphate buffer as described before (Minauro-Sanmiguel *et al.*, 2002). Bovine SMP were incubated at a concentration 1 mg/mL; liver and hepatoma SMP were cross-linked at a final concentration of 1.8 mg/mL, with the indicated concentrations of DSP. The reaction was carried out for 30 min at room temperature and arrested with 20 mM *L*-lysine.

Immunodetection of Cross-Linked Subunits

SDS-PAGE was carried out under nonreducing (without DTT) and reducing (+20 mM DTT) conditions. Afterwards, proteins were transferred 2 h to transfer membranes at 100 mA in a buffer containing 100 mM CAPS, 10% methanol, pH 11.0. Monoclonal antibodies (mAb) raised against recombinant rat liver IF₁ or bovine α subunit (García *et al.*, 1995) were used. Reactive bands were immunodetected with secondary goat antimouse IgG conjugated to HRP and the chemiluminescent ECL-Plus kit of Amersham-Pharmacia.

Purification of Recombinant Rat Liver IF₁ and Reconstitution Into Liver SMP

Sequence of the rat liver ATPase inhibitor protein was excised from the pMalIF1 fusion vector (kindly provided originally by Prof. Pedersen from Johns Hopkins University School of Medicine, Baltimore, USA)

using the synthetic oligonucleotides N1 (GGAATTC-CATATGGGGTTCGGACTCG) to insert a NdeI site at the 5' region of the sequence and the C1 (CC-CAAGCTTCAATGCTCACTATT) to insert a HindIII restriction site at the 3' region of the sequence. The PCR generated fragment was restricted with the NdeI and HindIII restriction enzymes and subcloned into a pIN-III-A3 derived IPTG inducible plasmid (Inouye and Inouye, 1985). The plasmid generated this way was transformed into the *Escherichia coli* BL21 strain for expression.

Protein Overexpression

The protein was overexpressed according to (Zheng *et al.*, 1993). The cultures were started by the addition of 2 mL of an overnight grown culture to a 500 mL LB medium. After 3 h of incubation (or Abs 600 nm = 0.5) at 37°C, the protein expression was induced by the addition of 0.4 mM IPTG, the incubation was continued overnight. The cells were harvested by centrifugation at 5000 rpm and washed twice with 100 mL saline solution. After overnight IPTG induction, cells were broken by sonication followed by DNase treatment. Cell debris were collected by 15,000 rpm centrifugation at 4°C and the supernatant was precipitated with 50% ammonium sulfate. After a second centrifugation, the supernatant was precipitated with 80% ammonium sulfate. The pellet was resuspended in 20 mM KH₂PO₄ buffer pH 8.0 and IF₁ was concentrated in Amicon membranes (10 kDa cutoff). Afterwards, pH was readjusted to 6.5 and the concentrated sample was loaded into a 3 mL CM-Sepharose column pre-equilibrated in the same buffer. IF₁ was eluted with a gradient of 20–600 mM of KH₂PO₄ and simultaneously a pH gradient of 6.5–8.7. The IF₁ sample was concentrated and desalted as described above and stored at –80°C until used. The purity of the sample was higher than 90% as judged by SDS-PAGE, Coomassie staining, and densitometry analyses (not shown). Pure recombinant IF₁ was reconstituted with liver SMP devoid of IF₁ as described by Lebowitz and Pedersen (1993).

Other Methods and Materials

The amount of protein in SMP, F₁F₀I, and F₁I preparations was measured with the method of Lowry *et al.* (1951). Densitometric analyses of Coomassie stained bands in SDS PAGE gels were carried out with the digital camera and imaging software "ALPHADIGIDOC" of Alpha Innotech Corporation according to the manufacturers instructions. In each gel the molecular weights of cross-linking products were calculated from interpolation using

the appropriate standards. The intensities of subunits were measured by peak integration after densitometry analyses. Coupling enzymes and substrates for ATPase activity were obtained from Sigma. Reactants for SDS PAGE were obtained from Bio-rad laboratories.

RESULTS

Several reports have shown a higher expression of IF₁ in cancerous cells in comparison with normal cells. In order to compare the amount of IF₁ expressed in normal and cancerous cells, we designed a Western-blot titration approach in which loading of 1–50 ng of pure recombinant IF₁ resulted in a linear increase in band intensity as calculated from densitometry analyses. Higher amounts of IF₁ saturated the chemiluminescent signal of the detection system (not shown). Therefore, we interpolated the intensities of the IF₁ band obtained in normal and hepatoma SMP that were in the linear range of the titration curve. After several preparations and experiments carried out with different amounts of loaded protein, we found that the amount of IF₁ in hepatoma was about twice of that found in normal SMP from rat liver (Fig. 1). The amount of IF₁ estimated in liver and hepatoma SMP were 0.55 ± 0.11 and 0.26 ± 0.04 nmol/mg, respectively. This value is higher than that previously reported by Schwerzmann *et al.* (1982) for whole mitochondria. This might reflect the increase in IF₁ content in SMP relative to mitochondria since according to these authors IF₁ is mostly associated to the inner mitochondrial membrane.

In order to assay the functional association of IF₁ with the ATP synthase in SMP from AS-30D hepatoma and liver, F₁F₀-ATPase activation assays were carried out. SMP were incubated in conditions that induce a progressive release of IF₁ to the media, i.e., pH 8.0, KCl 100 mM, and 40°C. At *t* = 0 before activation, the F₁F₀-ATPase of AS-30D SMP showed about half of the basal F₁F₀-ATPase activity of the normal rat liver enzyme (Fig. 2(A), *t* = 0). Time courses revealed that the F₁F₀-ATPase from AS-30D SMP was activated with a slower rate than the control enzyme of SMP (Fig. 2(A)). However, both SMP reached similar maximal F₁F₀-ATPase activities, although the enzyme from AS-30D hepatoma had a lower maximal ATPase rate. These results strongly suggest that in comparison with normal liver mitochondria, the higher expression of IF₁ in AS-30D hepatoma results in a better yield of productive association of IF₁ with the F₁F₀ complex. Furthermore, the total amount of F₁F₀-ATPase seems similar in AS-30D and normal liver mitochondria. According to maximal ATPase rates, if there is a difference in the F₁F₀-ATPase content in both systems, that should consist of a slightly lower amount of




Fig. 1. Amount of IF₁ in liver and hepatoma SMP with Westernblot and densitometry analyses. (A) The shown amounts of recombinant rat liver IF₁, liver (LSMP), and hepatoma (HSMP) submitochondrial particles were loaded on SDS-PAGE. Denaturing electrophoresis and WB were carried out as indicated in Materials and Methods with a mAb anti-IF₁. The two clear spots in the center of the immunoblot membrane correspond to 7 and 14 kDa molecular weight standards which are negatively developed with the chemiluminescent kit, therefore estimated the size of the IF₁ band is 10 kDa, the expected size of IF₁. (B) Densitometry analyses of each band was carried out as described in Materials and Methods. In the range of 1–50 ng of pure IF₁, the band intensity increased linearly. With higher IF₁ amounts the band intensity diminished due to signal saturation (not shown). The content of IF₁ in SMP was estimated with interpolation of the observed band intensities obtained with known amounts of SMP protein in this linear range of IF₁ titration.

F₁F₀-ATPase in AS-30D SMP. To confirm this, we carried out a simultaneous immunodetection of IF₁ and the α subunit of F₁. Densitometry analyses (Fig. 2(B)) showed that the relative amounts of α subunit was slightly lower in AS-30D SMP than in control rat liver particles (α AS-30D/ α liver = 0.9). However, the ratio of IF₁/ α intensities increased in AS-30D hepatoma (IF₁/ α = 1.2) relative to normal rat liver SMP (IF₁/ α = 0.8). These observations are in concordance with previous reports where the F₁F₀-ATPase was found reduced in rat hepatoma cells (Kuzela *et al.*, 1977). Furthermore, the β subunit was also found diminished in mitochondria derived from human cancer cells (Capuano *et al.*, 1996, 1997). Taken together, the functional and WB analyses show that IF₁ is indeed overexpressed in AS-30D cells in relation to ATP synthase expression leading to a better inhibition of the F₁F₀-ATPase in cancer cells.

To obtain structural evidence for the association of IF₁ with the ATP synthase, we carried out DSP cross-linking of IF₁ with rotor (γ , ϵ) and stator (α) subunits of the F₁F₀ complex as we described before with the bovine heart enzyme (Minauro-Sanmiguel *et al.*, 2002, and Fig. 3). SMP from liver and AS-30D hepatoma were incubated with DSP as described in Materials and Methods and cross-linking was arrested with L-Lysine. Afterwards, aliquots containing 30 μ g of protein were loaded into SDS-PAGE with or without reduction by DTT. Figure 3(B) shows that in the SMP from normal liver, essentially no cross-linked products were obtained. However, in the SMP from hepatoma, three cross-linking products were clearly defined of about 43, 46, and 67 kDa, according to computer calculations carried out as described in Materials and Methods. The products of lower molecular weight above IF₁ correspond to ϵ -IF₁ and IF₁-IF₁ cross-linkages




Fig. 2. Time course of F₁F₀-ATPase activation of liver and hepatoma SMP under conditions of IF₁ release. (A) Freshly prepared liver and hepatoma SMP were incubated at *t* = 0 in activation media as explained in Materials and Methods. At the times shown, 5 µL aliquots carrying 5 µg of protein were withdrawn for spectrophotometric measurement of ATPase activity. Basal activity at *t* = 0 was not modified by incubation of SMP in dilution media (see Materials and Methods) by 50 min. (B) Five micrograms of liver (LSMP) and hepatoma (HSMP) submitochondrial particles were loaded into SDS-PAGE and afterwards, Western blot was carried out as indicated in Materials and Methods with a mixture of anti-α and anti-IF₁ mAbs. Densitometry analyses showed the following band intensities in LSMP (IF₁ = 1724, α = 2440) and hepatoma (IF₁ = 2604, α = 2223) therefore, the IF₁/α ratios were 0.8 and 1.2 for liver and hepatoma SMP, respectively.

previously described (Minauro-Sanmiguel *et al.*, 2002), whereas the products of about 43 and 67 kDa correspond to γ-IF₁ and α-IF₁ cross-linkages that we found in the bovine heart enzyme. The identity of these products was confirmed with α and γ immunoblots, respectively (Minauro-Sanmiguel *et al.*, 2002). The product of about 46 kDa was not identified. The noncross-linked control of AS-30D SMP showed consistently about twice the intensity of the IF₁ monomer than in the normal liver SMP (Fig. 3(B), lanes 1 and 6). Formation of these cross-linked products was reversed by DTT reduction, except for the α-IF₁ product which, as in the bovine heart enzyme, was only partially reduced (Fig. 3(A)). Assuming that these




Fig. 3. IF₁ DSP cross-linking with ATP synthase subunits in bovine heart, rat liver, and rat hepatoma SMP. (A) Bovine heart SMP (1 mg/mL) were incubated by 30 min with the indicated amounts of DSP and cross-linking was arrested with 10 mM L-lysine. Afterwards, aliquots were withdrawn to load 20 µg of SMP protein in each lane of SDS-Page and anti-IF₁ Westernblot was carried out as described before. The previously identified α-IF₁ and γ-IF₁ products were observed besides a third 46 kDa product observed between them with 1 and 2 mg/mL of DSP. The presence of DTT reduced most of the γ-IF₁ and 46 kDa products as well as two smaller products that correspond to ε-IF₁ and IF₁-IF₁ cross-linkages (see Minauro-Sanmiguel *et al.*, 2002). (B) The same cross-linking, SDS-PAGE and WB procedures were followed with Liver and hepatoma SMP with the exception that the initial SMP protein concentration was 1.8 mg/mL and 40 µg of SMP protein were loaded per lane. The same α-IF₁, γ-IF₁, and 46 kDa products observed in bovine heart SMP (A) were also obtained in liver and hepatoma SMP. DTT (20 mM) reduced most of these products.

products could be formed with very low yields in SMP from normal liver, further gels were overloaded and the same products showed as faint bands (not shown).

In order to discard the possibility that the IF₁ cross-linkages observed in AS-30D hepatoma SMP could result from nonspecific interactions, we carried out an *in vitro*




Fig. 4. Reconstitution of recombinant IF₁ into F₁F₀-ATPase of rat liver SMP. The shown amounts of IF₁ were reconstituted into liver SMP as indicated in Materials and Methods and 10 µl aliquots containing 4 µg of protein were withdrawn for measurement of ATPase activity. Inset, the remaining of SMP samples were centrifuged once at 45,000 rpm in order to remove excess nonreconstituted IF₁ and the SMP pellets were dissolved directly in SDS-PAGE sample buffer to load 60 µg of SMP. Where indicated, 20 mM DTT was added 10 min before gel loading. Anti-IF₁ Western blot was carried out as described before.

reconstitution experiment as a model for the *in vivo* overexpression of IF₁ in cancer cells. Thus, recombinant rat liver IF₁ was reconstituted with SMP devoid of IF₁ before DSP cross-linking. Reconstitution produced about 90% inhibition of ATPase activity (Fig. 4) with an affinity similar to that previously reported by Lebowitz and Pedersen (1993) with recombinant rat liver IF₁. Western blotting of these reconstituted samples showed exactly the same DTT-sensitive cross-linking products as in the endogenous IF₁ overexpressed in cancer cells (Fig. 4, inset). As an additional control, we measured the IC₅₀ of recombinant IF₁ for the rat liver and hepatoma F₁F₀ complex of SMP devoid of IF₁ by titration and reconstitution experiments in order to confirm that the enzyme from hepatoma retained a similar affinity for IF₁. We found the same IC₅₀ of about 0.5 µg of IF₁ (Fig. 4) in liver and hepatoma SMP (not shown). Taken together, these experiments demonstrate structurally that the overexpression of IF₁ in AS-30D cells leads to a higher amount of endogenous IF₁ associated with the rotor and stator of the ATP synthase.

As a further effort to confirm that the observed IF₁-cross-linking products were formed within the intact F₁F₀I complex, the latter was immunoprecipitated as we described before for the bovine heart enzyme (Aggeler *et al.*, 2002; Minauro-Sanmiguel *et al.*, 2002). We obtained about half the yield of immunoprecipitated F₁F₀ from hepatoma than from liver SMP, consistent with the

lower amount of ATP synthase in the former system. DSP cross-linking decreased even further the yield of F₁F₀I complex. However, after loading about 5 µg of immunoprecipitated enzyme, the γ-IF₁ and α-IF₁ cross-linkages were detected almost exclusively in the enzyme immunoprecipitated from hepatoma SMP (Fig. 5). These results confirm that IF₁ is associated with higher yield in the F₁F₀I complex of hepatoma than in that of normal rat liver mitochondria.

DISCUSSION

This work shows the first structural evidence demonstrating that overexpression of the inhibitor protein (IF₁) in cancer cells produces a higher amount of association with the mitochondrial F₁F₀-ATP synthase than is found in normal cells. We developed a new approach of DSP cross-linking useful to assay the degree of association of IF₁ with the native ATP synthase in SMP. Furthermore, Western blot titration experiments allowed estimation of a 2-fold relative increase of IF₁ expression in mitochondria and SMP isolated from AS-30D cells relative to normal rat liver cells. Coimmunodetection of α and IF₁ subunits demonstrated that this overexpression is not a parallel increase of the whole F₁F₀ subunits, but that IF₁ is over-expressed in relation to the ATP synthase. Furthermore, our functional (Fig. 2(A)), WB (Fig. 2(B)), and immunoprecipitation studies indicate a tendency of AS-30D cancer cells to subexpress the F₁F₀ ATPase. These results are in concordance with previous reports where a lower amount of F₁F₀-ATPase was observed in other cancer cells (Capuano *et al.*, 1996, 1997; Kuzela *et al.*, 1977). Previous careful estimations have shown that rat liver IF₁ is expressed with a stoichiometry of 0.4 IF₁ molecules per ATP synthase (Schwerzmann *et al.*, 1982). Therefore, our determinations of 2.0-fold increase of IF₁ expression indicate that this ratio in AS-30D cancerous cells could be increased to 0.8, or higher, recalling the apparent lower content of F₁F₀ in comparison with normal cells. Thus, as predicted from previous functional studies (Chernyak *et al.*, 1994), IF₁ associates to F₁F₀ with better efficiency in cancerous cells than in normal cells.

In functional studies, the release of IF₁ demonstrated by ATPase activation was slower in AS-30D SMP than in the controls, indicating that the F₁F₀I complex formed in AS-30D mitochondria contains a higher amount of endogenous IF₁ (Fig. 2). Since the IF₁ cross-linkages obtained in both systems were the same, it seems that only the yield of IF₁ cross-linking products was increased in AS-30D SMP. According to our IF₁ saturation curves, this




Fig. 5. Cross-linking and immunoprecipitation of the F₁F₀I complex from liver and hepatoma SMP. (A) Rat liver F₁F₀I complex was immunoprecipitated from liver SMP and the purity and subunit composition was analyzed by SDS-PAGE. The identity of subunits was confirmed previously for the bovine heart enzyme (Aggeler *et al.*, 2002) and subunit composition was assumed the same for the rat liver enzyme. (B) Before and after DSP cross-linking, liver and hepatoma F₁F₀I complexes were immunoprecipitated from the corresponding SMP. After determination of protein, 5 μ g of immunoprecipitated F₁F₀ complexes were loaded per lane. The gel was over-run to improve resolution of IF₁ products. The main IF₁ band ran off from the gel. The γ -IF₁ and α -IF₁ products were detected in the F₁F₀I complex from hepatoma, but not in the enzyme immunoprecipitated from liver SMP. A faint band of α -IF₁ product was preserved in the F₁F₀I complex from liver SMP. No IF₁ product of 46 kDa was detected, however, the α -IF₁ and γ -IF₁ products were reduced by previous incubation with 10 mM DTT. The center empty lane contains molecular weight standards indicated as lines.

higher association of IF₁ with F₁F₀ in cancer cells is not the result of a shift in the affinity of the enzyme for IF₁. However, these results do not rule out structural differences among the F₁F₀I complexes of normal and AS-30D mitochondria. For example, the lower yield of immunoprecipitation of the F₁F₀I complex in AS-30D cancer cells might indicate structural differences with the normal rat liver F₁F₀I complex in addition to lower expression levels. We are in progress of site directed mutagenesis studies to identify the lysine residues of the rat liver IF₁ that form these cross-linking products by reconstitution of the recombinant IF₁ into rat liver SMP.

Taken together, these results provide structural and kinetic support to the previous proposals suggesting that cancer cells are protected more efficiently to prevent energy dissipation through the F₁F₀-ATPase activity since IF₁ is overexpressed and binds with higher efficiency to the enzyme.

ACKNOWLEDGMENTS

The critical review of this work is acknowledged to Professor Marietta Tuena de Gómez-Puyou from the National University of México. This work was supported by the grant number J34744-N from CONACyT, México. The AS-30D hepatoma cell line was kindly provided by Prof. Rafael Moreno-Sánchez of the Department of Biochemistry of the "Instituto Nacional de Cardiología de México." Plasmid pMalIF₁ was a generous gift of Prof. Roderick A. Capaldi, University of Oregon.

REFERENCES

- Aggeler, R., Coons, J., Taylor, S. W., Gosh, S. S., García, J. J., Capaldi, R. A., and Marusich, M. (2002). *J. Biol. Chem.* **277**, 33906–33912.
 Ala-Rämi, A., Ylitalo, K. V., y Hassinen, I. E. (2003). *Basic Res Cardiol.* **98**, 250–258.

- Capuano, F., Guerrieri, F., and Papa, S. (1997). *J. Bioenerg. Biomembr.* **29**, 379–384.
- Capuano, F., Varone, D., D'Eri, N., Russo, E., Tommasi, S., Montemurro, S., Prete, F., and Papa, S. (1996). *Biochem. Mol. Biol.* **38**, 1013–1022.
- Chang, J. P., Gibley, C. W., Jr., and Ichinoe, K. (1967). *Cancer Res.* **27**, 2065–2071.
- Chernyak, B. V., Dedov, V. N., and Gabai, V. L. (1994). *FEBS Lett.* **337**, 56–59.
- Chernyak, B. V., Dukhovich, V.F., and Khodjaev, E. Y. (1991). *Arch. Biochem. Biophys.* **286**, 604–609.
- García, J. J., Tuena de Gómez-Puyou, M., and Gómez-Puyou, A. (1995). *J. Bioenerg. Biomembr.* **27**, 127–136.
- Gómez-Puyou, A., Tuena de Gómez-Puyou, M., and Ernster, L. (1979). *Biochim. Biophys. Acta* **547**, 252–257.
- Harris, D. A., Von Tscharnner, V., and Radda, G. K. (1979). *Biochim. Biophys. Acta* **548**, 72–84.
- Inouye, S., and Inouye, M. (1985). *Nuclei Acids Res.* **9**, 3101–3110.
- Klein, G., Satre, M., Zaccari, G., and Vignais, P. V. (1982). *Biochim. Biophys. Acta* **681**, 226–232.
- Ko, H. Y., Delannoy, M., Hullihen, J., Chiu, W., and Pedersen, P. L. (2003). *J. Biol. Chem.* **278**, 12305–12309.
- Kuzela, S., Kolarov, J., Krempasky, V., Hatalova, I., Lakota, J., and Ujhazy, V. (1977). *Neoplasma* **24**, 559–562.
- Lebowitz, M. S., and Pedersen, P. L. (1993). *Arch. Biochem. Biophys.* **301**, 64–70.
- Lowry, O. H., Rosegrough, N. J., Farr, A. L., and Randall, R. J. (1951). *J. Biol. Chem.* **193**, 265–275.
- Luciakova, K., and Kuzela, S. (1984). *FEBS Lett.* **177**, 85–88.
- Minauro-Sanmiguel, F., Bravo, C., and García J. J. (2002). *J. Bioenerg. Biomembr.* **34**, 433–443.
- Moreadith, R., and Fiskum, G. (1984). *Anal. Biochem.* **137**, 360–367.
- Moreno-Sánchez, R. (1985). *J. Biol. Chem.* **260**, 4028–4034.
- Pullman, M. E., and Monroy, G. C. (1963). *J. Biol. Chem.* **238**, 3762–3769.
- Rouslin, W. (1991). *J. Bioenerg. Biomembr.* **23**, 873–888.
- Rouslin, W., and Broge, C. (1996). *J. Biol. Chem.* **271**, 23638–23641.
- Schwerzmann, K., Hullihen, J., and Pedersen, P. L. (1982). *J. Biol. Chem.* **257**, 9555–9560.
- Schwerzmann, K., and Pedersen, P. (1986). *Arch. Biochem. Biophys.* **250**, 1–18.
- Smith, D. F., Walborg, E. F., Jr., and Chang, J. P. (1970). *Cancer Res.* **30**, 2306–2309.
- Zheng, C. F., Wang, T. T., and Weiner, H. (1993). *Alcohol Clin. Exp. Res.* **17**, 828–831.